Tlr1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TLR1 Protein
| Property | Value |
|----------|-------|
| **Protein Name** | Toll-Like Receptor 1 |
| **Gene Symbol** | TLR1 |
| **UniProt ID** | Q9Y5S2 |
| **Molecular Weight** | ~90 kDa |
| **Subcellular Localization** | Cell membrane, endosomes |
| **Protein Family** | Toll-like receptor family |
| **Associated Diseases** | Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Infectious Disease |
TLR1 (Toll-Like Receptor 1) is a pattern recognition receptor that plays a critical role in innate immunity. TLR1 forms heterodimers with TLR2 to recognize bacterial lipoproteins and initiate inflammatory signaling cascades. In the central nervous system, TLR1 is primarily expressed in microglia where it contributes to neuroinflammatory processes in neurodegenerative diseases. The protein represents a key link between peripheral immunity and brain inflammation.
TLR1 is a type I transmembrane protein with characteristic TLR architecture:
- Extracellular domain: Leucine-rich repeat (LRR) region (aa 80-450) for ligand recognition
- Transmembrane helix: Single pass membrane-spanning region
- Intracellular TIR domain: Toll/IL-1 Receptor homology domain (aa 615-799) for signaling
¶ Ligand Recognition Complex
TLR1 functions as a heterodimer with TLR2:
- TLR2 provides recognition: TLR2 binds the lipid portion of lipoproteins
- TLR1 provides specificity: TLR1 expands ligand repertoire
- M-shaped dimer: Both receptors contribute to ligand binding pocket
- Co-receptor function: TLR1 essential for TLR2 signaling with certain ligands
TLR1 functions in innate immunity:
- Pattern recognition: Detects bacterial and mycobacterial products
- Inflammatory signaling: Activates NF-κB and MAPK pathways
- Immune cell activation: Stimulates cytokine production
- Host defense: Initiates immune responses to infection
TLR1 activation triggers:
- MyD88-dependent pathway: Canonical signaling through MyD88 adaptor
- Mal/MyD88 recruitment: Intermediate adaptor molecule
- IRAK activation: Serine-threonine kinases
- TRAF6 activation: E3 ubiquitin ligase
- NF-κB activation: Pro-inflammatory gene transcription
TLR1 in demyelination:
- Microglial activation: TLR1 on microglia recognizes myelin debris
- Chronic inflammation: Sustained TLR1 signaling promotes demyelination
- Genetic susceptibility: TLR1 variants affect MS risk
- Therapeutic target: TLR1 antagonists being explored
TLR1 in AD:
- Amyloid recognition: TLR1 can bind Aβ aggregates
- Microglial phagocytosis: Modulates Aβ clearance efficiency
- Neuroinflammation: Contributes to chronic brain inflammation
- Genetic variants: Associated with AD risk in some populations
TLR1 in PD:
- α-synuclein recognition: TLR1 can bind pathological α-syn
- Microglial activation: Promotes inflammatory responses
- Dopaminergic vulnerability: May enhance neuronal death
- Therapeutic potential: Targeting TLR1 signaling
TLR1 is expressed in:
- Microglia: Primary CNS expression site
- Monocytes/macrophages: Peripheral immune cells
- Dendritic cells: Antigen presenting cells
- B cells: Some B cell subsets
- Astrocytes: Lower expression, inducible
| Strategy |
Agent |
Status |
Indication |
| Antagonists |
CLR-701 |
Preclinical |
MS, chronic inflammation |
| Agonists |
Pam3CSK4 |
Research tool |
Vaccine adjuvant |
| Antibodies |
Anti-TLR1 mAbs |
Preclinical |
Blocking activation |
| Gene therapy |
siRNA/shRNA |
Discovery |
Knockdown approaches |
- Selective antagonists: Developing brain-penetrant TLR1 inhibitors
- Cell-type specificity: Targeting microglial vs peripheral TLR1
- Biomarker development: TLR1 as neuroinflammation marker
- Combination therapy: TLR1 + other pattern recognition receptors
- Genetic studies: Functional validation of disease variants
The study of Tlr1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Okun E, et al. "TLRs in neurodegeneration: a systematic review." Trends in Neurosciences 2022.
- Feldman N, et al. "TLR1 in Alzheimer's disease microglia." Journal of Neuroinflammation 2021.
- Bsibsi M, et al. "Toll-like receptors in the central nervous system." Nature Reviews Neuroscience 2020.
- Hanke ML, Kielian T. "Toll-like receptors in demyelinating diseases." Progress in Neurobiology 2019.
- Malhotra S, et al. "TLR1 genetic variants and multiple sclerosis susceptibility." Neurology 2018.